NASDAQ:NBSE

NeuBase Therapeutics (NBSE) Stock Forecast, Price & News

$0.18

0.00 (0.00%)

(As of 05/31/2023 ET)

Compare

Today's Range: $0.17
▼
$0.18
50-Day Range: $0.13
▼
$0.21
52-Week Range: $0.12
▼
$1.45

Volume: 137,957 shs
Average Volume: 436,879 shs
Market Capitalization: $6.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

NeuBase Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 6,076.3% Upside
$11.00 Price Target
Short Interest: Healthy
2.00% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.61
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.40) to ($0.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
NeuBase Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, NeuBase Therapeutics has a forecasted upside of 6,076.3% from its current price of $0.18.
Amount of Analyst Coverage
NeuBase Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.00% of the float of NeuBase Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
NeuBase Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NeuBase Therapeutics has recently increased by 0.71%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
NeuBase Therapeutics does not currently pay a dividend.
Dividend Growth
NeuBase Therapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
NeuBase Therapeutics has received a 78.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for NeuBase Therapeutics is -0.61.

2.0

News and Social Media Coverage

News Sentiment
NeuBase Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
Search Interest
14 people have searched for NBSE on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NeuBase Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.70% of the stock of NeuBase Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 37.21% of the stock of NeuBase Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for NeuBase Therapeutics are expected to grow in the coming year, from ($0.40) to ($0.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NeuBase Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NeuBase Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NeuBase Therapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NeuBase Therapeutics (NASDAQ:NBSE) Stock

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm's therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.

Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBSE Stock News Headlines

May 24, 2023 | finance.yahoo.com

NeuBase to Participate in Jefferies Healthcare Conference

May 22, 2023 | msn.com

NeuBase Releases Promising Preclinical Data From Stealth Editors To Achieve Gene Editing

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.

May 22, 2023 | finance.yahoo.com

NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™

May 16, 2023 | finance.yahoo.com

NeuBase Announces Formation of Gene Editing Advisory Board

May 12, 2023 | finanznachrichten.de

NeuBase Therapeutics, Inc.: NeuBase Reports Business Update and Financial Results for the First Quarter of 2023

May 11, 2023 | msn.com

NeuBase Therapeutics GAAP EPS of -$0.12 misses by $0.02

May 11, 2023 | finance.yahoo.com

NeuBase Reports Business Update and Financial Results for the First Quarter of 2023

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

May 2, 2023 | finance.yahoo.com

NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting

April 29, 2023 | americanbankingnews.com

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Short Interest Up 35.5% in April

April 20, 2023 | msn.com

Why MIND Technology Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

March 27, 2023 | msn.com

Why Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket

February 15, 2023 | finanznachrichten.de

NeuBase Therapeutics, Inc.: NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023

February 14, 2023 | finance.yahoo.com

NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023

December 29, 2022 | finance.yahoo.com

NeuBase Therapeutics selling stake in company to New York investment firm Alumni Capital

December 21, 2022 | finanznachrichten.de

NeuBase Therapeutics, Inc.: NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022

December 21, 2022 | nz.finance.yahoo.com

NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022

December 21, 2022 | finance.yahoo.com

NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022

October 24, 2022 | bizjournals.com

NeuBase Therapeutics to lose president

October 21, 2022 | bizjournals.com

NeuBase reaches research agreement on gene-editing platform

October 21, 2022 | finance.yahoo.com

NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company

October 17, 2022 | finance.yahoo.com

NeuBase Lays Off 60% Of Workforce, Reprioritizes Pipeline To Focus On Gene Editing Tech

October 17, 2022 | bizjournals.com

NeuBase Therapeutics begins strategic restructuring

October 14, 2022 | nasdaq.com

NeuBase Therapeutics Announces Restructuring Plan; To Cut Workforce By About 60%

October 14, 2022 | seekingalpha.com

NeuBase Therapeutics announces restructuring, to cut 60% of workforce

October 14, 2022 | finance.yahoo.com

NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBSE Company Calendar

Last Earnings: 5/11/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NBSE
CUSIP: N/A
CIK: 1173281
Web: www.neubasetherapeutics.com
Phone: (164) 645-1790
Fax: N/A
Employees: 33
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.00
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +4,672.6%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,780,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -114.12%
Return on Assets: -82.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.40
Quick Ratio: 7.40

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.43 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 33,810,000
Free Float: 27,826,000
Market Cap: $6.02 million
Optionable: Not Optionable
Beta: 1.01

Key Executives

Dietrich A. Stephan
Chief Executive Officer & Director

Todd P. Branning
Chief Financial Officer

Curt W. Bradshaw
Chief Scientific Officer

Anthony Rossomando
Chief Technology Officer

Ron Sarkar
Vice President-Business Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NBSE Stock - Frequently Asked Questions

Should I buy or sell NeuBase Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NBSE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NBSE, but not buy additional shares or sell existing shares.
View NBSE analyst ratings or view top-rated stocks.
What is NeuBase Therapeutics' stock price forecast for 2023?: 3 analysts have issued 12 month target prices for NeuBase Therapeutics' stock. Their NBSE share price forecasts range from $7.00 to $15.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 6,076.3% from the stock's current price.
View analysts price targets for NBSE or view top-rated stocks among Wall Street analysts.
How have NBSE shares performed in 2023?: NeuBase Therapeutics' stock was trading at $0.1902 at the beginning of the year. Since then, NBSE shares have decreased by 6.4% and is now trading at $0.1781.
View the best growth stocks for 2023 here.
When is NeuBase Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our NBSE earnings forecast.
How were NeuBase Therapeutics' earnings last quarter?: NeuBase Therapeutics, Inc. (NASDAQ:NBSE) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.02.
What other stocks do shareholders of NeuBase Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV).

What is NeuBase Therapeutics' stock symbol?: NeuBase Therapeutics trades on the NASDAQ under the ticker symbol "NBSE."
Who are NeuBase Therapeutics' major shareholders?: NeuBase Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.52%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Dietrich A Stephan, Eric I Richman, Todd P Branning and William Roland Mann.
View institutional ownership trends.
How do I buy shares of NeuBase Therapeutics?: Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NeuBase Therapeutics' stock price today?: One share of NBSE stock can currently be purchased for approximately $0.18.
How much money does NeuBase Therapeutics make?: NeuBase Therapeutics (NASDAQ:NBSE) has a market capitalization of $6.02 million. The company earns $-33,780,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.
How can I contact NeuBase Therapeutics?: NeuBase Therapeutics' mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The official website for the company is www.neubasetherapeutics.com. The company can be reached via phone at (164) 645-1790 or via email at daniel@lifesciadvisors.com.

This page (NASDAQ:NBSE) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial